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The art and science of drug titration
Aisling R. Caffrey  and Eric P. Borrelli
Abstract
A “one-size-fits-all” approach has been the standard for drug dosing, in particular for agents 
with a wide therapeutic index. The scientific principles of drug titration, most commonly 
used for medications with a narrow therapeutic index, are to give the patient adequate and 
effective treatment, at the lowest dose possible, with the aim of minimizing unnecessary 
medication use and side effects. The art of drug titration involves the interplay of scientific 
drug titration principles with the clinical expertise of the healthcare provider, and an 
individualized, patient-centered partnership between the provider and the patient to review 
the delicate balance of perceived benefits and risks from both perspectives. Drug titration 
may occur as up-, down-, or cross-titration depending on whether the goal is to reach or 
maintain a therapeutic outcome, decrease the risk of adverse effects, or prevent withdrawal/
discontinuation syndromes or recurrence of disease. Drug titration introduces additional 
complexities surrounding the conduct of clinical trials and real-world studies, confounding 
our understanding of the true effect of medications. In clinical practice, wide variations in 
titration schedules may exist due to a lack of evidence and consensus on titration approaches 
that achieve an optimal benefit-harm profile. Further, drug titration may be challenging for 
patients to follow, resulting in suboptimal adherence and may require increased healthcare-
related visits and coordination of care amongst providers. Despite the challenges associated 
with drug titration, it is a personalized approach to drug dosing that blends science with art, 
and with supportive real-world outcomes-based evidence, can be effective for optimizing 
pharmacotherapeutic outcomes and improving drug safety.
Plain language summary 
The art and science of finding the right dose
Summary: Changes to medication doses to achieve the best clinical response is known 
as drug titration. Drug titration is a way for clinicians to personalize medication doses 
so that patients can obtain the intended benefits of the treatment of their disease while 
minimizing side effects. This can occur by increasing the dose of a medication over time 
(up-titrating) until symptom relief occurs or a certain laboratory value is met, indicating 
that the most appropriate dose for that patient has been found. On the other hand, it 
can mean decreasing the dose of a medication over time (down-titrating) to lessen side 
effects or to find the lowest possible dose that keeps a patient’s symptoms or laboratory 
values under control. At times, up- and down-titrating may occur at the same time 
when one medication is being stopped and another is being started (cross-titration). For 
many medications, there may be limited scientific evidence to guide clinicians on the 
best schedule for changing medication doses. Further, dose changes can be difficult for 
clinicians to explain and for patients to follow. In addition, without proper coordination of 
care between providers, it may be difficult to properly manage adverse effects. Electronic 
health record systems need to implement new structures that capture medication dose 
changes, allowing better coordination of care and titration studies to identify schedules 
that achieve better patient outcomes and improve medication safety.
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Introduction
Establishing the precise dose for a drug is a com-
plex process. Historically, a single-dose regimen 
has been selected for agents with a wide therapeutic 
window, as minor changes in drug concentrations 
would have a limited impact on the efficacy and 
safety of the medication.1–3 However, a single-dose 
“one-size-fits-all” approach may not be equally 
effective and safe in all patients, and, therefore, 
multiple patient-level factors likely influence the 
optimal dose for an individual patient. Individual 
patient characteristics, including genetics, age, 
weight, renal and hepatic function, co-morbidities, 
and co-administration of other drugs, affect the 
dose a particular patient may require for a favorable 
risk–benefit ratio.4,5 In addition, pharmacokinetic 
(PK) (dose-concentration relationship) and phar-
macodynamic (PD) (concentration-effect relation-
ship) factors affect the amount of drug required,2,4,6 
including absorption, bioavailability, distribution, 
metabolism, and excretion, along with the mecha-
nism of action and the magnitude and duration of 
the clinical effect of the drug.5,7
Drug titration is a more individualized, patient-
centered approach to dosing, and is used in mul-
tiple therapeutic areas. Drug titration is common 
for agents with a narrow therapeutic index in 
order to optimize the therapeutic benefit while 
minimizing the risk of adverse effects, including 
drug–drug interactions.3,5 Some classic examples 
of drugs that require titration include antibiotics 
(e.g., aminoglycosides, vancomycin),8,9 anticoag-
ulants (e.g., warfarin),10 anticonvulsants (e.g., 
phenytoin),11 antidepressants (e.g., paroxetine),12 
antidiabetics (e.g., insulin, metformin),13 antipsy-
chotics (e.g., quetiapine),14 opioids (e.g,. mor-
phine),15 and stimulants (e.g., amphetamines).16 
In this narrative review, we discuss types of drug 
titration, titration schedules, challenges in drug 
titration, and opportunities to improve the art 
and science of drug titration.
Drug titration
Drug titration versus dose adjustment
Drug titration may be based on PK/PD parame-
ters, achievement of therapeutic outcomes, results 
of pharmacogenetic testing (PGT), and/or main-
tenance of drug safety.2,3,17 It is important to keep 
in mind the distinction between drug titration 
and dose adjustment. A dose adjustment is neces-
sary to maintain appropriate drug concentrations 
despite alterations in PK/PD parameters due to 
innate or external factors such as age, body weight 
(actual, ideal, or adjusted), drug interactions, 
metabolism, plasma protein binding, or renal/
hepatic impairment.2,3 Dose adjustment recom-
mendations can be found in prescribing informa-
tion and usually occur without a titration. For 
example, the dose of intravenous ciprofloxacin for 
an adult patient with chronic renal failure on 
hemodialysis is 400 mg every 24 h as compared 
with a dose of 400 mg every 12 h when a patient’s 
creatinine clearance (Clcr) is >30 ml/min for most 
infections.18,19 The recommended dose of riman-
tadine for influenza A prophylaxis in the elderly is 
100 mg orally daily (as opposed to twice daily), 
and the high-dose influenza vaccine is specifically 
approved for patients 65 years and older.20,21 The 
administration of efavirenz and voriconazole con-
currently is an example of a dose adjustment 
based on a drug–drug interaction. Efavirenz 
[always administered in combination with other 
antiretrovirals to provide a complete human 
immunodeficiency virus (HIV) regimen] is 
adjusted down to 300 mg/day orally when it is 
administered simultaneously with voriconazole, 
and the voriconazole dose is increased to 400 mg 
orally every 12 h.22 Lastly, ethambutol illustrates 
a dose adjustment based on weight: for patients 
weighing 40–55 kg, the recommended daily oral 
dose is 800 mg, for patients weighing 56–75 kg, 
the dose is 1200 mg, and for patients weighing 
76–90 kg, the dose is 1600 mg.23
Drug titration, in the traditional, scientific sense, 
is a change in dosing based on a specific PK/PD, 
clinical, pharmacogenetic, or laboratory parame-
ter, or is based on a set titration schedule as per 
the prescribing information. It is dosing that is 
individualized to the specific patient, with the goal 
of reaching a specific laboratory or clinical target 
with the lowest dose possible, while mitigating 
adverse effects, and/or preventing withdrawal/dis-
continuation symptoms or disease recurrence. It 
may be accomplished via up-titration (increasing 
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the dose over time), down-titration (decreasing 
the dose over time), or cross-titration (decreasing 
the dose of one drug while at the same time 
increasing the dose of another drug).3 A classic 
example of titration is the dosing of aminoglyco-
sides and vancomycin based on therapeutic drug 
concentrations. In general, gentamicin is dosed 
based on ideal body weight, starting with a loading 
dose of 1.5–2 mg/kg intravenously, followed by 
1–1.7 mg/kg (3–5 mg/kg/day) every 8 h with subse-
quent dose adjustments based on peak and trough 
concentrations and the minimum inhibitory con-
centration (MIC) of the bacterial pathogen.8 The 
goal is to maximize the peak concentration to 
MIC ratio (⩾8:1–10:1) to optimize bacterial kill-
ing.24 Vancomycin is dosed based on actual body 
weight, starting with a loading dose of 20–35 mg/
kg in critically ill patients, followed by 15–20 mg/
kg/dose every 8–12 h with subsequent dose adjust-
ments based on the ratio of the area under the 
curve (AUC) to the MIC of the bacterial patho-
gen.9 The aim of this dosing strategy is to sustain 
an AUC/MIC ratio of 400–600 for methicillin-
resistant Staphylococcus aureus infections to have 
the best chance of clinical treatment success with 
decreased potential for nephrotoxicity.9 Further, 
PGT plays a role in tailoring both drug selection 
and dosing with the intent of optimizing effective-
ness and minimizing adverse effects.17 PGT 
has been shown to be potentially helpful in 
these respects with anesthestics, anticonvulsants, 
antidepressants, antineoplastics, antiretrovirals, 
attention deficit hyperactivity disorder (ADHD) 
medications, mood stabilizers, and warfarin.17,25–31
The art versus science of drug titration
The scientific principles of drug titration are to 
give the patient adequate and effective treatment, 
at the lowest dose possible, with the aim of mini-
mizing unnecessary medication use and side 
effects.2,3 The art of drug titration involves the 
interplay of scientific drug titration principles 
with the clinical expertise of the healthcare pro-
vider, and an individualized, patient-centered 
partnership between the provider and the patient 
to review the delicate balance of perceived bene-
fits and risks from both perspectives. The art 
therefore takes into consideration what is realistic 
for a particular patient, including the intended 
therapeutic outcomes and management of drug 
titration based on each patient’s unique circum-
stances. This is an individualized approach that 
includes compromise and recognizes the patient’s 
autonomy, and evaluates the impact of positive 
and negative clinical outcomes, not just PK/PD 
and laboratory measurements. The patient fac-
tors that should be taken into account during the 
decision-making process may include, but are not 
limited to, the titration complexity, the patient’s 
expectations related to drug effectiveness and 
when therapeutic outcomes should occur, the 
severity of the disease, co-morbidities, concurrent 
medications, consequences of non-adherence, 
potential for and seriousness of adverse effects, 
personal priorities, health literacy, and socioeco-
nomic status. These factors inherently influence a 
patient’s willingness to adhere to a drug titration 
schedule, without which the benefits of the medi-
cation will not come to fruition.3,32–35 Artistry, 
rooted in scientific evidence, is used to select the 
most appropriate titration schedule for an indi-
vidual patient, in particular when multiple strate-
gies exist or strategies are less well-defined.
Titration schedule
The information regarding how to manage drug 
titration is usually provided in the prescribing 
information for the drug, evidence-based clinical 
practice guidelines, or various drug information 
resources. For some medications, set titration 
schedules may be recommended by the manufac-
turer, as found in the product label. Dose packs 
facilitate adherence by providers and patients to 
these recommended titration schedules, as seen 
with methylprednisolone and azithromycin.3,35–37 
Alternatively, response-guided titration may be 
used alone or in combination with target titration 
schedules per the package insert, as with antiepi-
leptic drugs.38 Ideally, for a response-guided 
approach to titrated drug dosing, there is an 
objective marker to measure the laboratory or 
clinical parameter of interest that guides the titra-
tion schedule.2 Example laboratory markers that 
guide titration include target international nor-
malized ratio (INR) with warfarin,39 target phe-
nytoin concentration with phenytoin,11 and target 
blood glucose concentrations during daily testing 
and hemoglobin A1c for long-term monitoring 
with insulin and oral diabetes medications.40 
When available, dosing algorithms based on PGT 
can be used to optimize the dose for individual 
patients, as has been demonstrated with warfarin 
and phenytoin.10,41,42 Clinical parameters may 
also be used to facilitate drug titration. Examples 
include antiepileptic drug doses titrated based on 
the reduction in seizure frequency or seizure 
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freedom,43 and antidepressants or opioids titrated 
based on scales that assess clinical response, such 
as the Hamilton Depression Rating Scale or the 
Visual Analog Scale, respectively.12,15
Providers may need to make exceptions to recom-
mended titration schedules and treatment goals 
as they may not meet the needs of all patients. 
The recommendations may be used as a starting 
point, with modifications made based on a 
patient’s specific needs. For example, when treat-
ing diabetes, hypertension, and hypercholester-
olemia, the adverse effect profiles of the drugs 
used to treat these diseases influence how aggres-
sive or cautious providers and patients may want 
to be with drug doses and titration schedules. 
There may be compromises to allow some degree 
of hyperglycemia to decrease the risk of hypogly-
cemia, some degree of hypertension to minimize 
the risk of hypotension, and some degree of 
hypercholesterolemia to prevent liver enzyme ele-
vations or myopathy.1 This type of customization, 
which showcases drug titration as a fusion of sci-
ence and art, is necessary to achieve effectiveness 
and maintain patient safety.
Up-titration
Up-titration is characterized by initiating therapy 
at a lower dose and increasing the dose over time 
to maintain or attain a specific response, or to 
decrease the risk of adverse effects. An example of 
up-titration to a specific therapeutic goal is the 
use of norepinephrine in the setting of sepsis and 
septic shock. The dose of norepinephrine is 
titrated up to achieve a mean arterial pressure of 
65 mmHg.44 Another example is semaglutide for 
the treatment of type 2 diabetes. The dose of 
semaglutide is titrated up to achieve glycemic 
control. Starting with an initial dose of 0.25 mg 
subcutaneously once weekly for 4 weeks, the dose 
is then increased to 0.5 mg once weekly for at 
least 4 weeks, and further increased to 1 mg once 
weekly if needed.45 Likewise, the oral semaglutide 
formulation also requires up-titration, beginning 
with a dose of 3 mg orally once daily for 30 days, 
followed by 7 mg orally once daily for 30 days. If 
additional glycemic control is needed, the dose 
may be increased to 14 mg orally once daily there-
after.46 With up-titration towards a specific thera-
peutic goal, it is important to keep in mind that 
there may be a point at which there is a ceiling 
effect in the response and continuing to increase 
the dose will not increase the effect, and may, in 
turn, put a patient at higher risk of adverse 
effects.3
Up-titration may be used to mitigate adverse 
effects. An example in oncology is the recom-
mended titration schedule for venetoclax, an 
agent used for the treatment of chronic lympho-
cytic leukemia and small lymphocytic lymphoma. 
In order to prevent tumor lysis syndrome from 
occurring, dosing with venetoclax is initiated at 
20 mg/day orally in week 1, then increased to 
50 mg/day in week 2, 100 mg/day in week 3, 
200 mg/day in week 4, and then 400 mg/day in 
week 5.47 Antiepileptic drugs are also up-titrated 
to minimize adverse effects. Perampanel dosing is 
started at 2 mg/day orally at bedtime with an up-
titration of 2 mg per week to achieve a target of 
4–12 mg/day to minimize dizziness.43 Lamotrigine 
is gradually up-titrated to reduce the risk of rash, 
in particular Stevens-Johnson syndrome or toxic 
epidermal necrolysis. There are 5-week starter kits 
available to assist patients with adherence to the 
titration schedule and specific dose titrations are 
recommended based on the patient’s age, weight, 
and concurrent medications.48 Antidepressants 
are another class of drugs that require up-titration 
to reduce adverse effects. Selective serotonin 
reuptake inhibitors are started at a lower dose and 
up-titrated over time to reduce the development 
of anxiety.49
Up-titration may also be necessary based on a 
specific PK/PD parameter. Carbamazepine 
undergoes self-induction of hepatic enzymes, 
which leads to an increase in its metabolism over 
time, thereby requiring an increase in dose over 
time in order to maintain appropriate concentra-
tions and a therapeutic effect.50 In contrast, 
patients with genetic variants of the cytochrome 
P450 enzymes CYP2C9*2 and CYP2C9*3 have a 
reduced ability to metabolize warfarin. Patients 
with these variants should be initially treated with 
a lower dose of warfarin and up-titrated more 
cautiously as they are at higher risk of developing 
supra-therapeutic international normalized ratios 
(INRs) and adverse effects.10
Up-titration may also be used for gradual 
improvement of symptoms or clinical outcomes 
while monitoring for adverse effects, particularly 
when optimal clinical effectiveness comes at the 
cost of dose-related side effects for drugs with 
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relatively narrow and specific therapeutic win-
dows.3 The art is in the partnership between the 
provider and patient for the management of side 
effects and occurs through the assessment of 
patient expectations and tolerance, as related to 
both presence and severity of negative effects. 
Therefore, the art includes the evaluation of any 
problems that the patient is experiencing to deter-
mine whether the dose is too high, too low, of 
insufficient duration to experience positive effects 
and/or for side effects to subside, and/or ineffec-
tive for that particular patient. This is demon-
strated in the treatment of ADHD, whereby 
treatment guidelines recommend four different 
approaches to up-titration: increasing the dose up 
to a dose beyond which there is no further 
improvement in symptoms, increasing the dose 
until the lowest dose that provides a response is 
achieved, increasing the dose until the maximum 
dose is reached, or increasing the dose until adverse 
effects occur.51 The success of the approach cho-
sen relies on communication between the pro-
vider and the patient at the onset of titration, 
continual input from the patient over the course 
of the titration, and a mutual understanding of 
the need for flexibility in the up-titration sched-
ule to maintain patient adherence.3 Based on 
the information the patient provides regarding 
symptom control and tolerability, the provider 
can alter the titration if doses are sub- or supra-
therapeutic. For this to occur, it is critical to 
have the patient’s (or patient proxy, e.g., par-
ent) assessment of the level of effectiveness of 
their functioning on different doses so subse-
quent titration is guided by input from the 
patient.
Down-titration
Down-titration is characterized by decreasing the 
dose over time once a specific response has been 
achieved, to either maintain a specific response 
while decreasing the risk of adverse effects or to 
prevent withdrawal or discontinuation syn-
dromes. There are many examples of medications 
for immunologic and inflammatory diseases that 
may require a dose decrease once their specific 
therapeutic goal has been achieved. Infliximab is 
a tumor necrosis factor inhibitor used to treat 
rheumatoid arthritis.52 In patients with stable low 
disease activity or disease remission, infliximab 
may be down-titrated from a dose of 3 mg/kg 
intravenously over time in order to discontinue 
the drug, although some patients may experience 
disease flares during this tapering process.52
The dosing of corticosteroids also highlights a 
down-titration approach. When corticosteroids 
are used for anti-inflammatory or immunosup-
pressive effects, for instance, in the treatment of 
asthma exacerbations, giant cell arteritis, rheuma-
toid arthritis, or systemic lupus erythematosus, 
they usually require an initial short course with 
dosing at the higher end of the dosing range to 
achieve prompt control of symptoms. This is then 
followed by gradual dose reductions over time to 
the lowest dose that maintains the clinical 
response or eventual discontinuation, thus mini-
mizing the serious side effects that can occur with 
long-term use of corticosteroids.36,53–56 A specific 
example in allergic conditions is the use of a 
methylprednisolone dose pack that starts with 
24 mg orally on day 1, 20 mg on day 2, 16 mg on 
day 3, 12 mg on day 4, 8 mg on day 5, and ends 
with 4 mg on day 6.54,55 In these cases, down titra-
tion is utilized when rapid control of a disease 
process is important and risks of acute toxicity 
from high doses are minimal, but there is signifi-
cant risk of harm associated with extended use of 
higher doses or with use at any dose for long 
durations.
Down-titration is also a method to prevent with-
drawal or discontinuation syndromes and/or 
other adverse effects. One example of this is the 
tapering of prednisone in patients receiving 
>20 mg/day orally (or the equivalent doses of 
other corticosteroids) for >3 weeks to prevent 
hypothalamic-pituitary-adrenal axis suppres-
sion.56,57 Another instance is the down-titration of 
antidepressants by decreasing the dose over sev-
eral weeks to prevent the discontinuation syn-
drome that may occur when stopping the 
medication.49 Lastly, tapering the doses of benzo-
diazepines gradually over approximately 4–8 weeks 
or more also illustrates the down-titration 
approach to decrease the risk of benzodiazepine 
withdrawal syndrome, which may include the 
development of seizures. Down-titration may also 
be based on a specific PK/PD parameter. As renal 
function declines over time, such as in the setting 
of acute kidney injury, certain drugs will be 
titrated based on the Clcr. For instance, when 
famotidine is used for the treatment of gastroe-
sophageal reflux disease, it is given as 20 mg orally 
twice daily. In the setting of renal impairment, 
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famotidine is given as 20 mg once daily when the 
Clcr is 30–60 ml/min and adjusted down to 20 mg 
every other day or 10 mg once daily when the Clcr 
is <30 ml/min. This approach is used to reduce 
the risk of adverse effects as the renal function 
declines.58 Changes in plasma protein binding of 
a drug may also necessitate a dose titration. 
Phenytoin concentrations need to be adjusted in 
patients with low albumin, which may then lead 
to the need for a decreased dose of phenytoin in 
order to lower the risk of supra-therapeutic con-
centrations and adverse effects.11
Down-titration poses a unique challenge as 
patients may be reluctant to decrease doses or 
discontinue drugs that have provided symptom 
control. Further, patients may not want to expe-
rience withdrawal or discontinuation syndromes. 
With down-titration, the provider must be skill-
ful in assuring the patient that the rate of down-
titration can be adjusted as needed and 
additional interventions can be used to help 
manage symptoms related to decreasing the 
dose.59,60 Like up-titration, providers may craft 
their own down-titration regimens when there is 
a lack of defined schedules, as with antidepres-
sants, benzodiazepines, biologics, and corticoster-
oids.36,52,56,59,60 The down-titration schedule is 
designed based on symptom severity, the urgency 
with which symptom relief is needed, the degree 
of clinical response, prior experience in clinical 
practice and/or in an individual patient, and the 
risks associated with recurrence of symptoms.52,54
Cross-titration
Cross-titration (or cross-tapering) in either direc-
tion may be performed when switching patients 
from one medication to another or to enable 
patients to be maintained on two medications, at 
times allowing both to be used at lower doses 
than when given alone.3,59 In the setting of cross-
titration, both evidence-based resources and clin-
ical expertise that apply to up- and down-titration 
need to be considered for each individual drug 
and patient, plus scrutiny regarding the safety of 
using two specific drugs concomitantly, with par-
ticular consideration given to adverse effects and 
drug interactions. A case in point is the titration 
of lamotrigine when a patient is concurrently tak-
ing valproate. In this setting, lamotrigine is 
titrated up, starting at a lower dose (25 mg every 
other day rather than 25 mg daily) than when 
prescribed alone. This titration schedule is 
adjusted to account for the interaction between 
the two agents that decreases the clearance of 
lamotrigine.48 Adding vasopressin, up to 
0.03 units/min, to decrease the norepinephrine 
dosage in sepsis and septic shock is an example of 
using a lower dose of one agent when it is used in 
combination with another drug. Using the drugs 
in combination allows a lower dose of norepi-
nephrine to be used while still maintaining mean 
arterial pressure. The benefit of this approach 
remains uncertain as no difference in mortality 
was found in the clinical trial that evaluated this 
practice. However, a subgroup analysis suggested 
improved survival in patients who received vaso-
pressin with norepinephrine doses <15 µg/min.44 
Lastly, cross-titration when switching antidepres-
sants highlights a down-titration of the current 
agent until it can be discontinued while concur-
rently starting a new agent and up-titrating its 
dose over time.59 This customized approach 
allows continued control of depression symptoms 
and avoidance of the antidepressant discontinua-
tion syndrome.59
Complexities of drug titration
Evidence
Drug titration is a form of personalized medi-
cine.2 There is mounting evidence that substan-
tial treatment heterogeneity exists in both clinical 
trials and real-world practice. This contradicts 
the notion that all patients being treated with a 
specific medication actually take the same dose, 
for the same duration, and in combination with 
the same concomitant medication(s).61–63 While 
it is becoming clearer that a “one-size-fits-all” 
approach is not optimal for drug dosing,17 clinical 
trials with titrated medications are complex, as 
comparisons between fixed-dose and dose-titra-
tion or between various dose-titration schedules, 
are difficult to study. Such challenges include the 
maintenance of blinding, external validity, and 
increased potential for post-randomization biases 
(i.e., differential loss to follow up, differential 
adherence, and differential discontinuation).
In addition, it is difficult to establish real-world 
evidence for titrated medications. When patients 
do not have the same drug exposures (drug, dose, 
duration, and concomitant medications), it is dif-
ficult to attribute specific clinical outcomes to 
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specific exposures. This challenge has been 
described in infectious diseases, in which it was 
found that treatment heterogeneity is nearly uni-
versal in bloodstream infections.62 Unfortunately, 
there is a lack of real-world exposure data for 
titrated medications, as data sources lack titration 
details. As a result, it is difficult to substantiate 
titration schedules, in terms of safety or effective-
ness, since supportive data are unavailable. 
Therefore, drug titration complicates our under-
standing of the effect of medications in real-world 
practice.
Due to the lack of real-world evidence for titrated 
medications, clinicians often must rely on data 
from clinical trials to inform their prescribing of 
schedules for drug titration, despite the afore-
mentioned clinical trial limitations. However, it is 
unclear whether titration schedules closely reflect 
titration from clinical trials and/or labeled titra-
tion, and some evidence suggests not only wide 
variation in titration schedules in clinical practice, 
but also divergence in titration schedules from 
clinical trials.43 For instance, a meta-analysis 
determined that, out of 11 randomized clinical 
trials and 38 cohort studies of methylphenidate 
for the treatment of ADHD in children, only 2 
and 8, respectively, reported their justification for 
the dose range used in the study.64 However, the 
justification was either unclear or did not match 
the cited source in most of these studies, high-
lighting the lack of evidence supporting titration 
schedules of methylphenidate in ADHD. In addi-
tion, there was a wide variation in the dose titra-
tion as the dose in the randomized clinical trials 
ranged from 20 to 72 mg/day, whereas in the 
cohort studies, it ranged from 20 to 60 mg/day.64 
Also, in patients on medications for heart failure, 
it was found that the up-titration schedules car-
ried out in clinical trials by dedicated research 
staff are not mirrored in the real-world setting, 
where lower doses are generally prescribed in 
contrast to the higher doses achieved in clinical 
trials.65
Consensus
There may be a lack of consensus on titration 
schedules that maximize benefits and minimize 
harms,3,49 or a lack of consensus on the therapeu-
tic and toxic concentration of the medication.3,11 
One example of a drug that has indication-based 
titration schedules is quetiapine. The initial dose 
and dose increases for the titration are dependent 
on whether the drug is being used for schizophre-
nia, bipolar mania, or bipolar depression.14 
Antiepileptic drugs demonstrate variability in 
therapeutic versus toxic drug concentration ranges. 
Some patients may experience seizure freedom at 
concentrations that are below the defined refer-
ence range, while others may have a reduction in 
seizures only when the concentrations are above 
the range, thus suggesting that each patient has his 
or her own individual target concentration.11 This 
highlights that, although there may be a recom-
mended titration schedule stemming from a “one-
size-fits-all” approach based on prescribing 
information or clinical guidelines, providers may 
need to craft a titration regimen to best fit the 
needs of an individual patient.
The benefits of up-titration to attain a specific 
response with certain medications has been 
uncertain. In 2002, the recommendation for 
patients undergoing elective noncardiac surgery 
per the American College of Cardiology/American 
Heart Association Guideline for Perioperative 
Cardiovascular Evaluation for Noncardiac 
Surgery was to prescribe a beta-blocker days or 
weeks before surgery and titrate the dose to 
achieve a heart rate of 50–60 beats/min.66 
However, in the 2014 guideline update, the rec-
ommendation was modified as the benefit of 
starting beta-blockers in naïve patients prior to 
surgery was called into question along with how 
to titrate them in this setting.67 Such uncertainly 
also exists with tapering (down-titrating) antide-
pressants. While some clinicians suggest decreas-
ing the dose by 25% per week until the 
antidepressant is discontinued, others recom-
mend decreasing the dose by 25% per month.59 
The protocol for benzodiazepine down-titration 
is also not well defined, as the recommendations 
range from decreasing the dose by 50% each week 
to decreasing it by 10–25% every 2 weeks.60 
Lastly, there may be an inability to measure 
objective outcomes without a specific marker for 
efficacy, effectiveness, or toxicity.2
Adherence
Further complicating the effectiveness and safety 
of drug titration is the inconvenience to the 
patient, which can impact medication adherence, 
including under-dosing (delay or failure to 
increase dose), over-dosing (initial high dose or 
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rapid dose increases), and/or missed dosing. Drug 
titration is also inconvenient in terms of health-
care-related visits for dose titrations and/or moni-
toring.1 Up to half of patients are non-adherent to 
their chronic medications, without taking into 
account the additional challenges surrounding 
dose titration,3,68 and non-adherence is associated 
with harmful health consequences and increased 
healthcare costs.17,35 As described earlier, patients 
may not take their medications or may not take 
them as prescribed, for numerous reasons, which 
includes complex regimens and adverse effects.3,35
Starter kits and dose packs, such as those men-
tioned previously for lamotrigine and methylpred-
nisolone, help to facilitate adherence to specific 
drug titration schedules.3,35,48,54,55 Titration packs 
are convenient for the provider and the patient, 
making it easier to adhere to a titrated regimen. 
However, they may not meet the needs of all 
patients, and, in some cases, may inadvertently 
cater to a “one-size-fits-all” approach and inter-
fere with personalized dosing.54,55
Although drug regimen complexity is recognized 
as a risk factor for non-adherence with certain 
medications, up-titration or down-titration also 
alleviates adverse effects, as has been described 
with antidepressants and anticonvulsants, poten-
tially leading to improved adherence by reducing 
treatment interruptions or discontinua-
tions.12,38,49,69–71 The need to coordinate care 
among providers and between providers and 
patients becomes more critical with drugs that 
require titration, both to monitor for effectiveness 
(or lack thereof) and adverse effects and to facili-
tate dose titration.3,65 However, clinicians have 
limited time, inadequate support structures, and 
unclear roles regarding drug titration.65
The complexities of drug titration affecting medi-
cation adherence are further complicated by 
multi-morbidity. Overall, medication utilization 
rates have increased over time, due to increases in 
available medications on the market to treat dis-
eases (e.g., medications for certain conditions 
were not previously available), as well as increased 
rates of chronic diseases due to the changing 
health and life expectancy of the population 
(increase in chronic diseases such as diabetes, 
high blood pressure, high cholesterol, and greater 
multi-morbidity in aging populations). Data from 
the 2010 National Health and Nutrition 
Examination Survey (NHANES) found that 
approximately 39% of people who are at least 
65 years of age were taking at least five prescrip-
tion medications.72 Patients taking complex med-
ication regimens have been shown to have worse 
medication adherence and patient outcomes. The 
addition of medications requiring titration adds 
further complexity to medication regimens for 
patients, making it more difficult to understand 
the dose and schedule, and, in turn, can reduce 
patient adherence.1,3,35
Various strategies have been deployed to improve 
and support drug titration in clinical practice. A 
multidisciplinary healthcare approach can help 
improve the quality of medication titration. In the 
setting of heart failure, clinician education, deci-
sion support and communication tools, post-pre-
scribing telephone monitoring of patients, 
auditing of clinicians, transitions of care and dis-
ease management services, and expanded pre-
scribing privileges for nurses and pharmacists 
have been used to enable a more individualized 
approach to pharmacotherapy.65 In addition, 
nurse-led titration services of heart failure medi-
cations have achieved target doses sooner while 
decreasing heart failure-related hospital admis-
sions and increasing patient survival.73 
Multidisciplinary teams that combine elements of 
the above-described approaches that take into 
account the best fit for the specific clinical prac-
tice site are more likely to be successful.65 Several 
studies have shown that pharmacist run titration 
services for insulin in patients with diabetes mel-
litus have resulted in improved glycemic con-
trol.74,75 Similar programs utilizing pharmacists 
have been effective in the management of antico-
agulation, neurologic conditions, and gout.76–78 
Appropriate drug titration that results in better 
patient outcomes may give rise to downstream 
cost savings. A study with PGT-guided therapy in 
bipolar disorder found a decrease in hospitaliza-
tions, a shorter duration of hospitalization, and 
less use of emergency medical services, ultimately 
leading to potential overall cost savings to the 
healthcare system, as compared with non-PGT 
guided therapy.79
Involving patients in the treatment decision-mak-
ing process can improve adherence, particularly 
when patient and provider expectations and 
responsibilities to each other are clearly estab-
lished.3 With a collaborative approach, patients 
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can take an active role in guiding their drug titra-
tions. For example, a majority of adults with 
ADHD can identify when the effects of their 
medications are wearing off.80 Providers can use 
this information to fine tune the drug titrations 
to improve symptom control over the course of 
the day.80 Moreover, advances in information 
technology should allow both clinicians and 
patients to be partners in this individualized 
approach to drug dosing.1 Information technol-
ogy, for instance, electronic medical record sys-
tems, should assist in the collection and analysis 
of data from the real-world setting, which can 
then be used to inform clinical decision making 
for personalized medicine.17
Costs
Medication titration is associated with excess 
healthcare resource utilization and healthcare 
costs. One study from a nationwide panel of neu-
rologists showed that, for patients utilizing antie-
pileptic drugs, periods of titration incurred higher 
healthcare resource utilization and costs com-
pared with maintenance periods.81 Similarly, an 
analysis of a large claims database found that for 
patients with major depressive disorder who initi-
ated therapy with a serotonin reuptake inhibitor, 
those who underwent dose titration experienced 
significantly higher healthcare resource utiliza-
tion and healthcare costs after 8 weeks of therapy 
compared with those who did not undergo 
titration.82
While PGT has the potential to reduce titration-
associated cost, some important factors to con-
sider for PGT are: who and when to test, which 
test to select, and how to interpret and use the 
test’s results.27,83 For certain conditions, provid-
ers may consider PGT to provide minimal clinical 
information, and, therefore, not worth the 
costs.27,83 Another barrier facing more widespread 
utilization of PGT in the United States is that 
third party payer reimbursement is highly variable 
depending upon the plan, the type of testing, and 
the specific test.83–86 Due to this, if PGT is not 
covered by insurance, it is not likely patients will 
pay out-of-pocket for the service, with a survey 
showing that almost half of patients would not 
pay any out-of-pocket costs for PGT.87
Titration can also lead to medication waste, as 
dose changes may require different prescriptions 
for different strengths and thus lead to leftover 
drug supply.88,89 Further, insurance plan policies 
present a barrier to titration due to drug supply 
requirements. For example, the 30- or 90-day 
supply requirement for coverage of the prescrip-
tion, despite titration occurring in shorter inter-
vals, leads to an excess of medication being 
dispensed to the patient.89,90 A complication of 
this excess supply, as observed with opioids and 
ADHD medications, is the potential for drug mis-
use or diversion.91–94 Titration can also lead to 
prescription refill issues. There is the potential for 
delay in therapy when the up-titration quantity 
exceeds therapeutic quantity limits for lower 
doses. In addition, up-titration with an existing 
prescription, as instructed by a provider directly 
to a patient, presents challenges at the time of 
refill since, without knowledge of the up-titration, 
insurance will consider it an early fill and deny 
coverage.95–98
Excess costs due to healthcare utilization and pre-
scriptions fills, and corresponding drug waste, 
represent opportunities for improvement in drug 
titration. Insurance companies should devise pro-
cedures and policies that support optimization of 
drug titration. Further, increased acceptance of 
telehealth could support healthcare visits specifi-
cally for titration, thus reducing associated health-
care costs of titration-related visits from both a 
health system perspective, as well as direct and 
indirect patient costs.
Summary
Drug titration is a form of personalized medicine, 
and many drugs in a variety of therapeutic areas 
require dose titration due to PK/PD and PGT 
parameters, to achieve specific therapeutic goals, 
and/or to decrease the risk of adverse effects. For 
some drugs, all of these factors may be interre-
lated, leading to the necessity of an individual-
ized, patient-centered approach that blends 
together the art and science of drug titration. This 
is in contrast to the population-based approach of 
“one-size-fits-all” dosing, which may not be as 
equally safe and effective among all patients.
There is a paucity of real-world data on the effec-
tiveness and safety of specific titration schedules 
among titrated medications, hence the varied 
approaches to titration and lack of titration con-
sensus for many medications. The widespread 
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use of electronic medical records and integration 
of medical and pharmacy records provides a 
unique opportunity to consistently and accurately 
capture titration details in a standardized man-
ner. In turn, such documentation will improve 
the coordination of care between providers and 
patients, and enable research that produces real-
world evidence to minimize harms and maximize 
positive clinical outcomes among titrated 
medications.
Authors’ note
The views expressed are those of the authors and 
do not necessarily reflect the position or policy of 
the United States Department of Veterans Affairs. 
This material is based upon work supported, in 
part, by the Office of Research and Development, 
Department of Veterans Affairs.
Acknowledgements
Dorothy McCoy, of MedVal Scientific 
Information Services (Princeton, NJ, USA) pro-
vided professional medical writing assistance to 
the authors. Dorothy McCoy performed a litera-
ture search and drafted/revised the manuscript.
Conflict of interest statement
ARC: Merck, Pfizer, Shionogi research funding; 
SK Life Science advisory board.
EPB: None.
Funding
The authors disclosed receipt of the following 
financial support for the research, authorship, 
and/or publication of this article: The assistance 
provided by MedVal Scientific Information 
Services was funded by SK Life Science, Inc., 
(Paramus, NJ, USA).
ORCID iD
Aisling R. Caffrey  https://orcid.org/0000-0002 
-4180-027X
References
 1. Trasta A. Personalized medicine and proper 
dosage: over- and undertreatment of chronic 
diseases endanger patients’ health and strain public 
health systems. EMBO Rep 2018; 19: e45957.
 2. Schuck RN, Pacanowski M, Kim S, et al. Use 
of titration as a therapeutic individualization 
strategy: an analysis of Food and Drug 
Administration-approved drugs. Clin Transl Sci 
2019; 12: 236–239.
 3. Maxwell S. Therapeutics and good prescribing. 
In: Walker BR, Colledge NR, Ralston SH, et al. 
(eds) Davidson’s principles and practice of medicine, 
22nd ed. Edinburgh, UK: Churchill Livingstone/
Elsevier, 2014, pp. 17–40.
 4. Chaturvedula A. Population pharmacokinetics. 
In: Jann MW, Penzak SR and Cohen LJ 
(eds). Applied clinical pharmacokinetics and 
pharmacodynamics of psychopharmacological agents. 
Cham, Switzerland: Adis, 2016, pp 71–90.
 5. Currie GM. Pharmacology, part 2: introduction 
to pharmacokinetics. J Nucl Med Technol 2018; 
46: 221–230.
 6. Holford NH. Clinical pharmacokinetics and 
pharmacodynamics of warfarin. Understanding 
the dose-effect relationship. Clin Pharmacokinet 
1986; 11: 483–504.
 7. Andrade EL, Bento AF, Cavalli J, et al. Non-
clinical studies in the process of new drug 
development - part II: good laboratory practice, 
metabolism, pharmacokinetics, safety and dose 
translation to clinical studies. Braz J Med Biol Res 
2016; 49: e5646.
 8. Edson RS and Terrell CL. The aminoglycosides. 
Mayo Clin Proc 1999; 74: 519–528.
 9. Rybak MJ, Le J, Lodise TP, et al. Therapeutic 
monitoring of vancomycin for serious methicillin-
resistant Staphylococcus aureus infections: a 
revised consensus guideline and review by the 
American Society of Health-System Pharmacists, 
the Infectious Diseases Society of America, the 
Pediatric Infectious Diseases Society, and the 
Society of Infectious Diseases Pharmacists. Am J 
Health Syst Pharm 2020; 77: 835–864.
 10. Shaw K, Amstutz U, Kim RB, et al. Clinical 
practice recommendations on genetic testing 
of CYP2C9 and VKORC1 variants in warfarin 
therapy. Ther Drug Monit 2015; 37: 428–436.
 11. Patsalos PN, Berry DJ, Bourgeois BFD, et al. 
Antiepileptic drugs—best practice guidelines for 
therapeutic drug monitoring: a position paper 
by the subcommission on therapeutic drug 
monitoring, ILAE commission on therapeutic 
strategies. Epilepsia 2008; 49: 1239–1276.
 12. Ielmini M, Poloni N, Caselli I, et al. Efficacy and 
tolerability of two different kinds of titration of 
paroxetine hydrocloride solution: an observational 
study. Psychopharmacol Bull 2018; 48: 33–41.
 13. Nathan DM, Buse JB, Davidson MB, et al. 
Medical management of hyperglycemia in type 2 
AR Caffrey and EP Borrelli et al.
journals.sagepub.com/home/taw 11
diabetes: a consensus algorithm for the initiation 
and adjustment of therapy: a consensus statement 
of the American Diabetes Association and the 
European Association for the Study of Diabetes. 
Diabetes Care 2009; 32: 193–203.
 14. SEROQUEL® (quetiapine fumarate). Prescribing 
information: SEROQUEL (quetiapine 
fumarate) tablets, for oral use. Wilmington, DE: 
AstraZeneca Pharmaceuticals LP, 2016.
 15. Aubrun F, Mazoit J-X and Riou B. Postoperative 
intravenous morphine titration. Br J Anaesth 
2012; 108: 193–201.
 16. ADDERALL XR® (mixed salts of a single-
entity amphetamine product). Prescribing 
information: ADDERALL XR (mixed salts 
of a single-entity amphetamine product) 
dextroamphetamine sulfate, dextroamphetamine 
saccharate, amphetamine aspartate monohydrate, 
amphetamine sulfate capsules, CII. Shire LLC, 
2013.
 17. Personalized Medicine Coalition. The 
personalized medicine report: opportunity, 
challenges, and the future. 2017, http://www.
personalizedmedicinecoalition.org/Userfiles/
PMC-Corporate/file/The_PM_Report.pdf 
(accessed 4 June 2020).
 18. Heintz BH, Matzke GR and Dager 
WE. Antimicrobial dosing concepts and 
recommendations for critically ill adult patients 
receiving continuous renal replacement therapy 
or intermittent hemodialysis. Pharmacotherapy 
2009; 29: 562–577.
 19. CIPRO IV® (ciprofloxacin). Prescribing 
information: CIPRO IV (ciprofloxacin) 
injection, for intravenous use. Bayer HealthCare 
Pharmaceuticals Inc., 2017.
 20. Grohskopf LA, Alyanak E, Broder KR, et al. 
Prevention and control of seasonal influenza 
with vaccines: recommendations of the Advisory 
Committee on Immunization Practices - United 
States, 2019-20 influenza season. MMWR 
Recomm Rep 2019; 68: 1–21.
 21. Fiore AE, Fry A, Shay D, et al. Antiviral agents 
for the treatment and chemoprophylaxis of 
influenza — recommendations of the Advisory 
Committee on Immunization Practices (ACIP). 
MMWR Recomm Rep 2011; 60: 1–24.
 22. Vadlapatla RK, Patel M, Paturi DK, et al. 
Clinically relevant drug-drug interactions 
between antiretrovirals and antifungals. Expert 
Opin Drug Metab Toxicol 2014; 10: 561–580.
 23. Nahid P, Dorman SE, Alipanah N, et al. Official 
American Thoracic Society/Centers for Disease 
Control and Prevention/Infectious Diseases 
Society of America clinical practice guidelines: 
treatment of drug-susceptible tuberculosis. Clin 
Infect Dis 2016; 63: e147–e195.
 24. McKinnon PS and Davis SL. Pharmacokinetic 
and pharmacodynamic issues in the treatment of 
bacterial infectious diseases. Eur J Clin Microbiol 
Infect Dis 2004; 23: 271–288.
 25. Ielmini M, Poloni N, Caselli I, et al. The role 
of pharmacogenetic testing in the treatment of 
bipolar disorder: preliminary results. Minerva 
Psichiatrica 2018; 59: 10–15.
 26. Ielmini M, Poloni N, Caselli I, et al. The utility of 
pharmacogenetic testing to support the treatment 
of bipolar disorder. Pharmgenomics Pers Med 
2018; 11: 35–42.
 27. Hippman C and Nislow C. Pharmacogenomic 
testing: clinical evidence and implementation 
challenges. J Pers Med 2019; 9: 40.
 28. Brown JT, Abdel-Rahman SM, van Haandel L, 
et al. Single dose, CYP2D6 genotype-stratified 
pharmacokinetic study of atomoxetine in children 
with ADHD. Clin Pharmacol Ther 2016; 99: 
642–650.
 29. Michelson D, Read HA, Ruff DD, et al. CYP2D6 
and clinical response to atomoxetine in children 
and adolescents with ADHD. J Am Acad Child 
Adolesc Psychiatry 2007; 46: 242–251.
 30. Cheon K-A, Jun J-Y and Cho D-Y. Association 
of the catechol-O-methyltransferase 
polymorphism with methylphenidate response 
in a classroom setting in children with 
attention-deficit hyperactivity disorder. Int Clin 
Psychopharmacol 2008; 23: 291–298.
 31. Kereszturi E, Tarnok Z, Bognar E, et al. 
Catechol-O-methyltransferase Val158Met 
polymorphism is associated with methylphenidate 
response in ADHD children. Am J Med Genet B 
Neuropsychiatr Genet 2008; 147B: 1431–1435.
 32. Bloomgarden Z. Adherence and diabetes. J 
Diabetes 2018; 10: 692–694.
 33. Shahin W, Kennedy GA and Stupans I. The 
impact of personal and cultural beliefs on 
medication adherence of patients with chronic 
illnesses: a systematic review. Patient Prefer 
Adherence 2019; 13: 1019–1035.
 34. McCarthy S. Pharmacological interventions for 
ADHD: how do adolescent and adult patient 
beliefs and attitudes impact treatment adherence? 
Patient Prefer Adherence 2014; 8: 1317–1327.
 35. Neiman AB, Ruppar T, Ho M, et al. CDC grand 
rounds: improving medication adherence for 
12 journals.sagepub.com/home/taw
Therapeutic Advances in Drug Safety 11
chronic disease management - innovations and 
opportunities. MMWR Morb Mortal Wkly Rep 
2017; 66: 1248–1251.
 36. Medrol® (methylprednisolone). Prescribing 
information: Medrol (methylprednisolone) 
tablets, USP. New York, NY: Pharmacia & 
Upjohn Co, 2019.
 37. ZITHROMAX® (azithromycin). Prescribing 
information: ZITHROMAX (azithromycin) 250 
mg and 500 mg tablets, for oral use, for oral 
suspension. New York, NY: Pfizer Laboratories, 
Division of Pfizer Inc., 2019.
 38. Panayiotopoulos CP. (ed) Principles of therapy 
in epilepsies. In: The Epilepsies: seizures, syndromes 
and management. Oxfordshire, UK: Bladon 
Medical Publishing, 2005.
 39. Limdi NA and Veenstra DL. Expectations, 
validity, and reality in pharmacogenetics. J Clin 
Epidemiol 2010; 63: 960–969.
 40. Liebl A, Prusty V, Valensi P, et al. Ten years of 
experience with biphasic insulin aspart 30: from 
drug development to the latest clinical findings. 
Drugs 2012; 72: 1495–1520.
 41. Silvado CE, Terra VC and Twardowschy CA. 
CYP2C9 polymorphisms in epilepsy: influence 
on phenytoin treatment. Pharmgenomics Pers Med 
2018; 11: 51–58.
 42. Fricke-Galindo I, Jung-Cook H, LLerena A, 
et al. Pharmacogenetics of adverse reactions to 
antiepileptic drugs. Neurologia 2018; 33: 165–176.
 43. Trinka E, Steinhoff BJ, Nikanorova M, et al. 
Perampanel for focal epilepsy: insights from early 
clinical experience. Acta Neurol Scand 2016; 133: 
160–172.
 44. Rhodes A, Evans LE, Alhazzani W, et al. 
Surviving sepsis campaign: international 
guidelines for management of sepsis and septic 
shock: 2016. Crit Care Med 2017; 45: 486–552.
 45. Goldenberg RM and Steen O. Semaglutide: 
review and place in therapy for adults with type 2 
diabetes. Can J Diabetes 2019; 43: 136–145.
 46. RYBELSUS® (semaglutide). Prescribing 
information: RYBELSUS (semaglutide) tablets, 
for oral use. Plainsboro, NJ: Novo Nordisk, 2019.
 47. Itchaki G and Brown JR. The potential of 
venetoclax (ABT-199) in chronic lymphocytic 
leukemia. Ther Adv Hematol 2016; 7: 270–287.
 48. LAMICTAL® (lamotrigine). Prescribing 
information: LAMICTAL (lamotrigine) tablets, 
for oral use, chewable dispersible tablets, for 
oral use. LAMICTAL ODT (lamotrigine) orally 
disintegrating tablets, for oral use. Research Triangle 
Park, NC: GlaxoSmithKline, 2019.
 49. American Psychiatric Association. Practice 
guideline for the treatment of patients with major 
depressive disorder. Washington, DC: American 
Psychiatric Association, 2010.
 50. Tolou-Ghamari Z, Zare M, Habibabadi 
JM, et al. A quick review of carbamazepine 
pharmacokinetics in epilepsy from 1953 to 2012. 
J Res Med Sci 2013; 18(Suppl. 1): S81–S85.
 51. Huss M, Duhan P, Gandhi P, et al. 
Methylphenidate dose optimization for ADHD 
treatment: review of safety, efficacy, and clinical 
necessity. Neuropsychiatr Dis Treat 2017; 13: 
1741–1751.
 52. Lau CS, Gibofsky A, Damjanov N, et al. 
Down-titration of biologics for the treatment 
of rheumatoid arthritis: a systematic literature 
review. Rheumatol Int 2017; 37: 1789–1798.
 53. Strehl C, Ehlers L, Gaber T, et al. 
Glucocorticoids-all-rounders tackling the versatile 
players of the immune system. Front Immunol 
2019; 10: 1744.
 54. Strauss RA. The use of a tapering dose of 
methylprednisolone for asthma exacerbations: is 
it adequate? J Allergy Clin Immunol Pract 2013; 1: 
695–697.
 55. Waljee AK, Rogers MA, Lin P, et al. Short term 
use of oral corticosteroids and related harms 
among adults in the United States: population 
based cohort study. BMJ 2017; 357: j1415.
 56. Liu D, Ahmet A, Ward L, et al. A practical 
guide to the monitoring and management of the 
complications of systemic corticosteroid therapy. 
Allergy Asthma Clin Immunol 2013; 9: 30.
 57. Paragliola RM, Papi G, Pontecorvi A, et al. 
Treatment with synthetic glucocorticoids and the 
hypothalamus-pituitary-adrenal axis. Int J Mol Sci 
2017; 18: 2201.
 58. PEPCID® (famotidine). Prescribing information: 
PEPCID (famotidine) tablets, for oral use. South 
Granville, Australia: Merck Sharp & Dohme 
(Australia) Pty Ltd., 2018.
 59. Ogle NR and Akkerman SR. Guidance for the 
discontinuation or switching of antidepressant 
therapies in adults. J Pharm Pract 2013; 26: 389–396.
 60. Soyka M. Treatment of benzodiazepine 
dependence. N Engl J Med 2017; 376: 1147–1157.
 61. Hernán MA and Hernández-Díaz S. Beyond the 
intention-to-treat in comparative effectiveness 
research. Clin Trials 2012; 9: 48–55.
AR Caffrey and EP Borrelli et al.
journals.sagepub.com/home/taw 13
 62. Caffrey AR, Babcock ZR, Lopes VV, et al. 
Heterogeneity in the treatment of bloodstream 
infections identified from antibiotic exposure 
mapping. Pharmacoepidemiol Drug Saf 2019; 28: 
707–715.
 63. Deschaseaux C, McSharry M, Hudson E, et al. 
Treatment initiation patterns, modifications, and 
medication adherence among newly diagnosed 
heart failure patients: a retrospective claims 
database analysis. J Manag Care Spec Pharm 
2016; 22: 561–571.
 64. Ching C, Eslick GD and Poulton AS. Evaluation 
of methylphenidate safety and maximum-dose 
titration rationale in attention-deficit/hyperactivity 
disorder: a meta-analysis. JAMA Pediatr 2019; 
173: 630–639.
 65. Atherton JJ and Hickey A. Expert comment: is 
medication titration in heart failure too complex? 
Card Fail Rev 2017; 3: 25–32.
 66. Eagle KA, Berger PB, Calkins H, et al. ACC/
AHA guideline update for perioperative 
cardiovascular evaluation for noncardiac 
surgery—executive summary: a report of the 
American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines 
(committee to update the 1996 guidelines on 
perioperative cardiovascular evaluation for 
noncardiac surgery). J Am Coll Cardiol 2002; 39: 
542–553.
 67. Fleisher LA, Fleischmann KE, Auerbach AD, 
et al. 2014 ACC/AHA guideline on perioperative 
cardiovascular evaluation and management 
of patients undergoing noncardiac surgery: a 
report of the American College of Cardiology/
American Heart Association Task Force on 
practice guidelines. J Am Coll Cardiol 2014; 64: 
e77–e137.
 68. Morris LS and Schulz RM. Patient compliance—
an overview. J Clin Pharm Ther 1992; 17: 
283–295.
 69. Perucca P and Gilliam FG. Adverse effects of 
antiepileptic drugs. Lancet Neurol 2012; 11: 
792–802.
 70. Cramer JA, Mintzer S, Wheless J, et al. Adverse 
effects of antiepileptic drugs: a brief overview of 
important issues. Expert Rev Neurother 2010; 10: 
885–891.
 71. Biton V, Gil-Nagel A, Brodie MJ, et al. Safety 
and tolerability of different titration rates of 
retigabine (ezogabine) in patients with partial-
onset seizures. Epilepsy Res 2013; 107: 138–145.
 72. Charlesworth CJ, Smit E, Lee DSH, et al. 
Polypharmacy among adults aged 65 years and 
older in the United States: 1988-2010. J Gerontol 
A Biol Sci Med Sci 2015; 70: 989–995.
 73. Driscoll A, Currey J, Tonkin A, et al. Nurse-
led titration of angiotensin converting enzyme 
inhibitors, beta-adrenergic blocking agents, and 
angiotensin receptor blockers for people with 
heart failure with reduced ejection fraction. 
Cochrane Database Syst Rev 2015; CD009889.
 74. Rochester CD, Leon N, Dombrowski R, et al. 
Collaborative drug therapy management for 
initiating and adjusting insulin therapy in patients 
with type 2 diabetes mellitus. Am J Health Syst 
Pharm 2010; 67: 42–48.
 75. Weidman-Evans E, Evans J, Eastwood R, et al. 
Implementation of a pharmacist-run telephonic 
insulin titration service. J Am Pharm Assoc (2003) 
2012; 52: e266–e272.
 76. Bungard TJ, Gardner L, Archer SL, et al. 
Evaluation of a pharmacist-managed 
anticoagulation clinic: improving patient care. 
Open Med 2009; 3: e16–e21.
 77. Martin AW, Heberle AP and Knight JM. 
Interventions associated with implementation of a 
pharmacist-led neurology pharmacotherapy clinic 
in an ambulatory care setting. J Am Coll Clin 
Pharm 2019; 2: 116–122.
 78. Huang IJ, Liew JW, Morcos MB, et al. 
Pharmacist-managed titration of urate-lowering 
therapy to streamline gout management. 
Rheumatol Int 2019; 39: 1637–1641.
 79. Callegari C, Isella C, Caselli I, et al. 
Pharmacogenetic tests in reducing accesses to 
emergency services and days of hospitalization in 
bipolar disorder: a 2-year mirror analysis. J Pers 
Med 2019; 9: 22.
 80. Brown TE, Romero B, Sarocco P, et al. The 
patient perspective: unmet treatment needs 
in adults with attention-deficit/hyperactivity 
disorder. Prim Care Companion CNS Disord 2019; 
21: 18m02397.
 81. Fishman J, Kalilani L, Song Y, et al. Antiepileptic 
drug titration and related health care resource use 
and costs. J Manag Care Spec Pharm 2018; 24: 
929–938.
 82. Camacho F, Kong MC, Sheehan DV, et al. 
Expenditures associated with dose titration 
at initiation of therapy in patients with major 
depressive disorder: a retrospective analysis of a 
large managed care claims database. P T 2010; 
35: 452–468.
 83. Moyer AM and Caraballo PJ. The challenges of 
implementing pharmacogenomic testing in the 
14 journals.sagepub.com/home/taw
Therapeutic Advances in Drug Safety 11
clinic. Expert Rev Pharmacoecon Outcomes Res 
2017; 17: 567–577.
 84. Lu CY, Loomer S, Ceccarelli R, et al. Insurance 
coverage policies for pharmacogenomic and multi-
gene testing for cancer. J Pers Med 2018; 8: 19.
 85. Hresko A and Haga SB. Insurance coverage 
policies for personalized medicine. J Pers Med 
2012; 2: 201–216.
 86. Keeling NJ, Rosenthal MM, West-Strum D, et al. 
Preemptive pharmacogenetic testing: exploring 
the knowledge and perspectives of US payers. 
Genet Med 2019; 21: 1224–1232.
 87. Bielinski SJ, St Sauver JL, Olson JE, et al. Are 
patients willing to incur out-of-pocket costs for 
pharmacogenomic testing? Pharmacogenomics J 
2017; 17: 1–3.
 88. Bettington E, Spinks J, Kelly F, et al. Returning 
unwanted medicines to pharmacies: prescribing 
to reduce waste. Aust Prescr 2018; 41: 78–81.
 89. Bekker CL, van den Bemt BJF, Egberts ACG, 
et al. Patient and medication factors associated 
with preventable medication waste and 
possibilities for redispensing. Int J Clin Pharm 
2018; 40: 704–711.
 90. Liberman JN and Girdish C. Recent trends in 
the dispensing of 90-day-supply prescriptions 
at retail pharmacies: implications for improved 
convenience and access. Am Health Drug Benefits 
2011; 4: 95–100.
 91. Berge KH, Dillon KR, Sikkink KM, et al. 
Diversion of drugs within health care facilities, 
a multiple-victim crime: patterns of diversion, 
scope, consequences, detection, and prevention. 
Mayo Clin Proc 2012; 87: 674–682.
 92. Compton WM, Han B, Blanco C, et al. 
Prevalence and correlates of prescription 
stimulant use, misuse, use disorders, and 
motivations for misuse among adults in the 
United States. Am J Psychiatry 2018; 175: 
741–755.
 93. Han B, Compton WM, Blanco C, et al. 
Prescription opioid use, misuse, and use disorders 
in U.S. adults: 2015 National Survey on drug use 
and health. Ann Intern Med 2017; 167: 293–301.
 94. Brady KT, McCauley JL and Back SE. 
Prescription opioid misuse, abuse, and treatment 
in the United States: an update. Am J Psychiatry 
2016; 173: 18–26.
 95. Sinsky TA and Sinsky CA. A streamlined 
approach to prescription management. Fam Pract 
Manag 2012; 19: 11–13.
 96. Andersson K, Melander A, Svensson C, et al. 
Repeat prescriptions: refill adherence in relation 
to patient and prescriber characteristics, 
reimbursement level and type of medication. Eur 
J Public Health 2005; 15: 621–626.
 97. Amin K, Farley JF, Maciejewski ML, et al. 
Effect of medicaid policy changes on medication 
adherence: differences by baseline adherence. J 
Manag Care Spec Pharm 2017; 23: 337–345.
 98. Taitel M, Fensterheim L, Kirkham H, et al. 
Medication days’ supply, adherence, wastage, 
and cost among chronic patients in Medicaid. 
Medicare Medicaid Res Rev 2012; 2: E1–E13.
Visit SAGE journals online 
journals.sagepub.com/
home/taw
SAGE journals
